[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Johns Hopkins All Children's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":171},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,59,89,117,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100394283","phase-2-tcr-alpha-beta-t-cell-depleted-haploidentical-hct-in-the-treatment-of-primary-immunodeficiency-and-inherited-metabolic-disorders-in-children-100394283",false,"NCT04414046","TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children","Study of TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Hematopoietic Cell Transplantation From Haploidentical Donors in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children","Inclusion Criteria:\n\n1. Patient with any form of primary immune deficiency\u002Fdysregulatory disorders characterized by aberrant immune function, abnormal hematopoiesis, systemic or organ specific autoimmunity and\u002For non-malignant lymphoproliferation. This includes, but not limited to:\n\n   I. Disorders of phagocytes: Chronic granulomatous disease, Leukocyte adhesion deficiency, defects of IL-10 pathway, MonoMac syndrome\n\n   II. Defects of cellular and humoral immunity: Severe Combined Immunodeficiency Disorder (infants with classic SCID up to 2 years of age will be excluded due to other open protocol), X-linked hyper-IgM syndrome, DOCK8 deficiency, ZAP70 deficiency, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, NEMO deficiency.\n\n   III. Disorder of immune dysregulation: Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, CTLA4 deficiency, LRBA deficiency, STAT1 GOF, STAT3 GOF, X-linked lymphoproliferative disease etc.\n\n   IV. Other PIDs and immune dysregulatory disorders who can be benefitted by HCT as deemed appropriate by the PI and the treating immunologist.\n2. Histiocytic disorders including hemophagocytic lymphohistiocytosis (familial HLH (types 1-5), secondary HLH (refractory to therapy or with recurrent episodes of hyper inflammation) and multisystem refractory Langerhans cell histiocytosis.\n3. Metabolic disorders that could improve or stabilize after stem cell transplantation such as mucopolysaccharidoses, neurodegenerative disorders, osteopetrosis, etc.\n\nInclusion Criteria:\n\n1. Patient has a suitable genotypic identical match of 5\u002F10. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1.\n2. Patients must have adequate organ function measured by:\n\n   1. Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 40% or SF ≥ 26%\n   2. Pulmonary: asymptomatic or if symptomatic DLCO ≥ 40% of predicted (corrected for hemoglobin) or pulse oximetry ≥ 92% on room air if the patient is unable to perform pulmonary function testing.\n   3. Renal: Creatinine clearance (CrCl) or glomerular filtration rate (GFR) must be \\> 50 mL\u002Fmin\u002F1.73 m2.\n   4. Hepatic: Serum conjugated (direct) bilirubin \\\u003C 2.0 x ULN for age; AST and ALT \\\u003C 5.0 x ULN for age.\n   5. Karnofsky or Lansky (age-dependent) performance score ≥ 50\n3. Signed written informed consent\n\nExclusion Criteria:\n\n1. Participants who have an HLA-matched sibling who is able and willing to donate bone marrow. Patients with a HLA-matched unrelated donors are not excluded.\n2. Pregnant or breastfeeding females.\n3. Patient has HIV or uncontrolled fungal, bacterial or viral infections.\n4. Patient has received prior solid organ transplant.\n5. Patient has active GVHD (\\> grade II) or chronic extensive GVHD due to a previous allograft at the time of inclusion.","ALL","21 Years",{"count":19,"type":20},17,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This research is being done to learn if a new type of haploidentical transplantation using TCR alpha beta and CD19 depleted stem cell graft from the donor is safe and effective to treat the patient's underlying condition. This study will use stem cells obtained via peripheral blood or bone marrow from parent or other half-matched family member donor. These will be processed through a special device called CliniMACS, which is considered investigational.",[26,27],"Primary Immune Deficiency Disorders","Metabolic Disease","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":32},"2020-07-22",{"date":36,"type":20},"2027-06-30",{"name":38,"class":39},"Johns Hopkins All Children's Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":17,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":24,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":57,"leadSponsor":58,"locationsCount":40},"100389867","phase-2-tcr-alpha-beta-t-cell-depleted-haploidentical-hct-in-the-treatment-of-non-malignant-hematological-disorders-in-children-100389867","NCT04356469","TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children","Study of TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Hematopoietic Cell Transplantation From Haploidentical Donors in the Treatment of Non-Malignant Hematological Disorders in Children","Inclusion Criteria:\n\n1. Severe sickle cell disease (HbSS, HbSC, HbSB0, HbSB+, HbSD, HbSE) with at least one of the following criteria:\n\n   1. Cerebrovascular accident lasting longer than 24 hours\n   2. Impaired neuropsychological function with abnormal brain MRI\u002FMRA\n   3. Patients with frequent (≥ 3 per year for preceding 2 years) painful vaso-occlusive episodes\n   4. Recurrent (≥ 3 in lifetime) acute chest syndrome events which have necessitated erythrocyte transfusion therapy\n   5. Any combination of ≥ 3 acute chest syndrome episodes and vaso-occlusive pain episodes yearly for 3 years and have failed treatment with hydroxyurea (HU) (at least 6 months on maximum tolerated dose) or who are intolerant to HU therapy\n2. Thalassemia major with at least one of the following criteria:\n\n   1. Transfusion dependency defined as receiving 8 or more transfusions per year\n   2. Thalassemia diagnosis documented by clinical assessment, laboratory evidence with microcytic anemia and absence of HbA (\\\u003C 10%) on electrophoresis and or confirmation by DNA analysis of alpha and beta gene loci\n   3. Genotypically proven thalassemia major for children \\\u003C 2 years of age even in the absence of transfusion dependency\n   4. Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor response to chelation therapy)\n3. Bone marrow failure syndromes and autoimmune cytopenias:\n\n   1. Severe Aplastic Anemia refractory to immunosuppressive therapy\n   2. Diamond Blackfan Anemia refractory to conventional therapy\n   3. Inherited Bone Marrow Failure Syndromes such as Fanconi anemia and Shwachman-Diamond syndrome with progressive marrow failure (without cytogenetic evidence of MDS\u002FAML)\n   4. Severe Congenital Neutropenia\n   5. Congenital Amegakaryocytic Thrombocytopenia\n   6. Glanzmann Thrombasthenia\n   7. Autoimmune Cytopenias refractory to conventional treatment (including Pure red cell aplasia, Evan's syndrome, Immune thrombocytopenia, autoimmune hemolytic anemia)\n   8. Other marrow failure disorders not otherwise specified\n\nInclusion Criteria:\n\n1. Patient has a suitable genotypic identical match of 5\u002F10. The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1.\n2. Patients must have adequate organ function measured by:\n\n   1. Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 40% or SF ≥ 26%\n   2. Pulmonary: asymptomatic or if symptomatic DLCO ≥ 40% of predicted (corrected for hemoglobin) or pulse oximetry ≥ 92% on room air if the patient is unable to perform pulmonary function testing.\n   3. Renal: Creatinine clearance (CrCl) or glomerular filtration rate (GFR) must be \\> 50 mL\u002Fmin\u002F1.73 m2.\n   4. Hepatic: Serum conjugated (direct) bilirubin \\\u003C 2.0 x ULN for age as per local laboratory unless attributable to Gilbert's syndrome; AST and ALT \\\u003C 5.0 x ULN for age as per local laboratory. Patients with hyperbilirubinemia as a consequence of hyperhemolysis, or a profound change in serum hemoglobin post blood transfusion, are not excluded.\n   5. Karnofsky or Lansky (age-dependent) performance score ≥ 50\n3. Signed written informed consent\n\nExclusion Criteria:\n\n1. Participants who have an HLA-matched sibling who is able and willing to donate bone marrow. Patients with a HLA-matched unrelated donors are not excluded.\n2. Pregnant or breastfeeding females.\n3. Patient has HIV or uncontrolled fungal, bacterial or viral infections.\n4. Patient has received prior solid organ transplant.\n5. Patient has active GVHD (\\> grade II) or chronic extensive GVHD due to a previous allograft at the time of inclusion.\n6. For patients with hemoglobinopathy, liver biopsy is necessary if the patient has received chronic transfusions for over a year and has two ferritin levels of ≥ 1000 ng\u002Fml. Patients with cirrhosis, extensive bridging hepatic fibrosis, or active hepatitis are excluded from enrollment.","0 Years",{"count":19,"type":20},[23],[52,53,54],"Hemoglobinopathy (Disorder)","Severe Aplastic Anemia","Bone Marrow Failure Syndrome",{"date":31,"type":32},{"date":34,"type":32},{"date":36,"type":20},{"name":38,"class":39},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100564407","phase-3-collaborative-risk-stratified-investigation-in-thrombosis-prone-inpatients-with-critical-illness-anticoagulation-with-lmwh-in-teens-for-thromboprophylaxis-critical-teens-tp-100564407","NCT06628778","Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).","Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP)","Inclusion Criteria:\n\n* Admission Age between 12- 18 years of age\n* Within 24 hours of pediatric intensive care unit (PICU) admission for enrollment\n* Presence of a Central Venous Catheter\n* Presumed or confirmed infection or systemic inflammatory condition\n\nExclusion Criteria:\n\n* Active treatment for VTE or known VTE present prior to or on pediatric intensive care unit (PICU) admission\n* Current receipt of an antithrombotic agent excluding unfractionated heparin for vascular catheter patency\n* Active ISTH-defined clinically relevant bleeding\n* Surgery in the last 7-days\n* Major trauma within the last 7-days\n* Admission for management of congenital heart disease including perioperative management of critical congenital heart disease\n* Presence of coagulopathy including:\n* International normalized ratio (INR) 2.0 activated partial thromboplastin time (aPTT) 50 seconds Platelet count 50 x103\u002FmL\n* Creatinine clearance 30 ml\u002Fmin\u002F1.73 m2\n* Known hypersensitivity to heparin or pork products\n* Laboratory confirmed heparin induced thrombocytopenia\n* Current pregnancy or lactation,\n* Presence of an epidural catheter\n* Prior enrollment in the CRITICAL-Teens-TP Trial","12 Years","18 Years",{"count":69,"type":20},802,[71],"PHASE3","Critically ill adolescents are at greatest risk for developing hospital-acquired venous thromboembolism. To date, no phase 3 randomized controlled trials have been conducted for pharmacological thromboprophylaxis as primary venous thromboembolism prevention in children. The investigators will perform a United States definitive multicenter phase 3 randomized controlled trial of the low molecular weight heparin enoxaparin as primary venous thromboembolism prophylaxis among critically ill adolescents who are classified a priori as high risk based upon the investigators validated risk prediction models.",[74],"Venous Thromboembolism (VTE)",[76,77,78,79],"pediatric","adolescent","critical illness","thromboprophylaxis","NOT_YET_RECRUITING","2026-05-21",{"date":83,"type":32},"2026-05-26",{"date":85,"type":20},"2027-04-15",{"date":87,"type":20},"2035-04-15",{"name":38,"class":39},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":101,"conditions":102,"keywords":106,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":40},"100542739","feasibility-and-acceptability-of-internet-based-parent-child-interaction-therapy-i-pcit-in-pediatric-cancer-100542739","NCT06346782","Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer","Feasibility, Acceptability, and Preliminary Efficacy of an Internet-based Parent-child Interaction Therapy (I-PCIT) Intervention for Children With Cancer","I-PCIT","Inclusion Criteria:\n\n* Participants will be parents of 2-12 year-old children who (1) currently or previously received cancer treatment and\u002For long-term cancer follow-up care at Johns Hopkins All Children's Hospital (JHACH).\n* The child's cancer treatment must have included or plan to include chemotherapy and\u002For radiation.\n* The child's cancer diagnosis must have been conferred at least 6 weeks prior to study enrollment. If a patient's cancer relapses during the study period, the patient's oncologist must agree to the patient continuing in this intervention.\n* The parent must have access to reliable internet service (e.g., in their own home, in a friend or family member's home, via cell phone carrier) and their own smartphone, tablet, or computer to participate in telehealth intervention sessions.\n\nExclusion Criteria:\n\n* Parents will be excluded if they or their child have cognitive, motor, or language delays that would preclude participation, as observed by research staff or listed in the child's medical record. Hearing impaired parents will also be excluded because I-PCIT requires the coach to verbally coach parents via bug-in-ear.\n* Parents will be excluded if their child is expected to undergo bone marrow transplant (BMT) during the study or has received BMT within 2 months of study enrollment.\n* The child must not be receiving end of life care, as determined by medical chart review and\u002For consultation with the patient's medical team.",{"count":98,"type":20},300,[100],"NA","This study is being done to learn whether a telehealth intervention called \"Internet-Based Parent Child Interaction Therapy,\" or I-PCIT,\" can help parents improve the child's behavior if the child currently or previously went through cancer treatment.\n\nParents who choose to be in this study will complete a survey to help researchers figure out if the parent is eligible for the larger study. If a parent is eligible for the larger study and chooses to participate, if so, the participants will be randomly assigned to either receive the I-PCIT intervention now or to be on a waitlist and begin I-PCIT in 5-6 months. The whole study consists of completing I-PCIT sessions with a clinician and completing 3-4 follow-up surveys after the initial screener survey.",[103,104,105],"Pediatric Cancer","Oncology","Disruptive Behavior",[103,104,107,108,105],"Parent","Parenting","2026-04-27",{"date":111,"type":32},"2026-04-30",{"date":113,"type":32},"2024-02-19",{"date":115,"type":20},"2028-08-01",{"name":38,"class":39},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":40},"100627958","phase-2-pediatric-asthma-trial-of-corticosteroid-heterogeneity-patch-trial-of-dexamethasone-versus-methylprednisolone-for-pediatric-critical-asthma-100627958","NCT07455396","Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma","Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): A Phase 2 Prospective Randomized Open Blinded End-point (PROBE) Design, Randomized Clinical Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma","PATCH","Inclusion Criteria:\n\n* Age 3-17 years\n* Intensive care unit admission\n* Treatment for critical asthma\n\nExclusion Criteria:\n\n* History of unrepaired critical congenital heart disease\n* History of cystic fibrosis\n* Active tracheostomy dependence","3 Years","17 Years",{"count":128,"type":20},159,[23],"Acute asthma exacerbation is caused by dysregulated pulmonary inflammatory pathways such that standard treatment includes prompt administration of exogenous systemic corticosteroids (SCs), but there remains an ongoing dialogue among the expert medical community regarding the superiority of specific SCs including dose, frequency of administration, route, and delivery. Regimens are often chosen based on provider preference, and different strategies include once-daily dosing (ODD) dexamethasone (DM) 0.6 mg\u002Fkg\u002Fdose for 2 days, every 6 hours (q6h) DM 0.25 mg\u002Fkg\u002Fdose for 2 days, and methylprednisolone (MP) 1 mg\u002Fkg\u002Fdose every 6 hours for 5-days.\n\nTo address this knowledge gap, the investigators plan to perform a single-center, phase 2, randomized clinical trial of children 3-17 years of age hospitalized for critical asthma (CA) randomized to one of three regimens above. The study would be powered to evaluate rates of additional prescriptions of SC and also secondarily evaluate quality of life metrics.",[132],"Asthma (Diagnosis)",[134,135,136,137,138,139],"pediatric critical asthma","pediatric intensive care unit","status asthmaticus","systemic corticosteroids","methylprednisolone","dexamethasone","2026-03-03",{"date":142,"type":32},"2026-03-06",{"date":144,"type":20},"2026-05-15",{"date":146,"type":20},"2028-05-14",{"name":38,"class":39},{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":126,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":40},"100533285","phase-2-azithromycin-for-critical-asthma---pediatrics-100533285","NCT06223828","Azithromycin for Critical Asthma - Pediatrics","Azithromycin as Immunomodulation Among Children Hospitalized for Critical Asthma: A Prospective, Open-Label, Non-Randomized, Interventional Study With Parallel Biospecimen Banking","CR-AZI Kids","Inclusion criteria\n\n* Age 3-17 years\n* Admission to the PICU\n* Primary diagnosis of critical asthma\n* Prescription for continuous inhaled beta-agonist therapy and\u002For intravenous (IV) beta-agonist therapy\n* Prescription for intravenous systemic corticosteroids\n\nExclusion criteria\n\n* Critical Congenital Heart Disease Unrepaired\n* Tracheostomy Dependence at Admission\n* Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication\n* Past Medical History of Prolonged QT Syndrome or Arrhythmias\n* Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension",{"count":157,"type":20},100,[23,71],"The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.",[161,162],"Pediatric Asthma","Critical Illness","2025-12-16",{"date":165,"type":32},"2025-12-17",{"date":167,"type":32},"2024-04-02",{"date":169,"type":20},"2026-12-31",{"name":38,"class":39},""]